The Cardiovascular Risk Picture for Men
Cardiovascular disease (CVD) is the leading cause of death in men globally, with men developing coronary heart disease approximately 10 years earlier than women on average. Key modifiable risk factors include:
- Elevated LDL cholesterol and triglycerides
- Low HDL cholesterol
- Hypertension
- Insulin resistance and type 2 diabetes
- Chronic inflammation (elevated CRP)
- Endothelial dysfunction (impaired arterial lining function)
- Excess visceral fat
Supplements cannot replace medications when risk factors require pharmaceutical management. However, certain supplements have genuine evidence for supporting cardiovascular biomarkers — as adjuncts to diet, exercise, and medical care, not as replacements.
If you have diagnosed cardiovascular disease, significant risk factors, or are on cardiovascular medications, supplement decisions should be made in consultation with a cardiologist or primary care physician. Some supplements interact with medications (e.g., omega-3 at high doses can increase bleeding risk with anticoagulants).
Omega-3 Fatty Acids
Triglyceride Reduction: Strongest Evidence
Omega-3 fatty acids (EPA and DHA) have the most robust cardiovascular evidence of any supplement category:
Triglycerides: At doses of 2–4g EPA+DHA/day, omega-3s consistently reduce triglycerides by 20–35%. This is FDA-recognized — prescription omega-3s (Lovaza, Vascepa) are approved specifically for hypertriglyceridemia.
A 2012 meta-analysis (American Journal of Clinical Nutrition, Balk et al.) of 48 RCTs confirmed significant triglyceride reduction with omega-3 supplementation.
The REDUCE-IT Trial (2018): A landmark RCT (NEJM, Bhatt et al., n=8,179) found high-dose icosapentaenoic acid (EPA only, 4g/day as Vascepa) in high-risk patients on statins reduced major cardiovascular events by 25% and cardiovascular death by 20%. This was a striking finding, though the use of mineral oil as the control arm has been controversial.
STRENGTH Trial (2020): Tested a combined EPA+DHA product (4g/day) in similar high-risk patients and found no significant reduction in cardiovascular events — suggesting EPA specifically (without DHA) may be what drives the REDUCE-IT benefit, though this remains debated.
For most men at moderate risk: 1–2g EPA+DHA/day from quality fish oil may support triglycerides and has a favorable safety profile. The very large cardiovascular outcome benefits were at 4g/day in specifically high-risk populations.
CoQ10 (Ubiquinol/Ubiquinone)
Statin-Related Considerations
Statins inhibit HMG-CoA reductase — the same pathway used to synthesize CoQ10. This has led to the hypothesis that statin use depletes CoQ10 and contributes to muscle side effects (myalgia).
Blood CoQ10 and statins: Multiple studies confirm statins reduce blood CoQ10 levels by 30–50%. However, whether blood CoQ10 reflects muscle tissue CoQ10 is debated.
RCT evidence for statin myalgia: Results are mixed. A 2015 Cochrane-style review found insufficient evidence to conclude CoQ10 reduces statin-associated muscle symptoms, though several trials showed benefits and the study quality was variable.
Heart failure evidence: The strongest CoQ10 cardiovascular RCT is in heart failure:
A 2014 multicenter RCT (Q-SYMBIO trial, JACC Heart Failure, Mortensen et al., n=420) found CoQ10 (300mg/day for 2 years) in chronic heart failure patients significantly reduced major adverse cardiovascular events (14% vs. 25% in placebo) and cardiovascular mortality. This is a notable finding in a specific, serious cardiovascular population.
Hypertension: A 2007 meta-analysis of 12 RCTs (Journal of Human Hypertension, Rosenfeldt et al.) found CoQ10 supplementation significantly reduced systolic blood pressure by an average of 17 mmHg and diastolic by 10 mmHg. Effect sizes were substantial, though trials were smaller.
For general cardiovascular support: 100–300mg/day is the range used in most trials. Ubiquinol (reduced form) may have better absorption, particularly in older adults.
Magnesium
Blood Pressure and Cardiac Function
Magnesium plays roles in:
- Vascular smooth muscle relaxation (vasodilation)
- Calcium channel function in cardiac muscle
- Regulation of sodium-potassium ATPase (electrolyte balance in cardiac cells)
- Insulin sensitivity and glucose metabolism
Hypertension evidence: A 2016 meta-analysis (Hypertension, Zhang et al.) of 34 RCTs found magnesium supplementation significantly reduced systolic blood pressure by 2 mmHg and diastolic by 1.78 mmHg on average — small but consistent effects that are meaningful at a population level.
Cardiac arrhythmia: Magnesium deficiency is strongly associated with cardiac arrhythmias. IV magnesium is used clinically for treatment of certain arrhythmias and in acute MI. Whether oral supplementation reduces arrhythmia risk is less established.
Insulin sensitivity: Magnesium is a cofactor for insulin receptor function. Multiple studies link low magnesium with insulin resistance and type 2 diabetes risk — a significant cardiovascular risk factor.
A 2013 meta-analysis found dietary magnesium intake inversely associated with all-cause and cardiovascular mortality, with a dose-response relationship.
Typical dose: 200–400mg elemental magnesium/day (glycinate or citrate preferred for tolerability).
Berberine: The Multitarget Cardiovascular Agent
Berberine's cardiovascular evidence is extensive, including direct effects on lipids, blood sugar, and blood pressure.
Lipid Management
LDL cholesterol: A 2015 meta-analysis (Evidence-Based Complementary and Alternative Medicine, Li et al.) of 27 RCTs found berberine significantly reduced LDL by approximately 20–25mg/dL, total cholesterol, and triglycerides — while raising HDL.
Berberine's LDL-lowering mechanism includes PCSK9 inhibition (upregulating LDL receptor expression) and LDLR (LDL receptor) upregulation — a mechanism that is additive to and different from statins.
A 2012 study (American Journal of Cardiology, Kong et al.) found berberine combined with a low-dose statin produced greater LDL reduction than the statin alone, without additional side effects.
Blood Glucose
As covered in the fasting mimetics article, berberine has evidence equivalent to metformin for blood glucose control in type 2 diabetes — highly relevant for cardiovascular risk since diabetes is one of the strongest CVD risk factors.
Blood Pressure
Some evidence for modest blood pressure reduction, likely via endothelial function improvement and AMPK-mediated vasodilation.
Typical dose: 500mg two to three times daily with meals. Significant drug interactions exist — particularly with statins (CYP3A4 inhibition), anticoagulants, and hypoglycemic medications.
Building a Cardiovascular Supplement Protocol
| Supplement | Primary Benefit | Dose Range | Key Caveat |
|---|---|---|---|
| Omega-3 (EPA+DHA) | Triglyceride reduction; anti-inflammatory; anti-arrhythmic | 1–4g/day (2–4g for TG reduction) | High dose increases bleeding risk with anticoagulants |
| CoQ10 | Blood pressure support; mitochondrial function; heart failure support | 100–300mg/day (ubiquinol) | Most benefit in heart failure, hypertension, or statin users |
| Magnesium | Blood pressure; insulin sensitivity; cardiac electrolyte balance | 300–400mg elemental/day | Laxative at high doses; avoid oxide form |
| Berberine | LDL reduction; blood glucose; multiple CVD risk factors | 500mg two to three times daily | Multiple drug interactions; GI side effects common |
The sequence of testing matters: baseline lipid panel, fasting glucose, blood pressure, and CRP allows targeted supplement selection based on which risk factors are actually elevated.
Related: Omega-3 Supplement Guide: EPA vs. DHA, Fish vs. Algae, and What Research Shows · Male Fertility and Supplements: CoQ10, Zinc, Selenium, and Antioxidant Research · Supplement Stack Audit
Be the first to try Prova
We're building an app to track whether cardiovascular health and tracking actually works. Join the waitlist.